Texas Children's Hospital
ASO as a feasible therapy to treat MECP2 duplication disorder
March 4, 2021
A study by Dr. Zoghbi provides experimental evidence that supports the use of antisense oligonucleotides as a feasible strategy to treat MECP2 Duplication Syndrome. Funding for this work came from the MECP2 Duplication Syndrome Fund at RSRT.